Special Issue

Emerging Insights into Malaria

Message from the Guest Editors

Despite the efforts and measures implemented over many years to control malaria, it is still one of the most prevalent public health concerns in the world. Several studies have been performed in recent decades to elucidate the mechanisms involved in its pathogenesis and host-parasite relationship, the discovery of novel drugs for treatment and chemoprevention, and the application of vaccines and methodology employed for vector control, among others. The results of this and future research may elucidate mechanisms that support the goals of malaria control and elimination. This Special Issue will address all research that provides new insights into the pathogenesis, novel treatments or treatment regimens, diagnostic methodologies, and control of malaria vector mosquitoes.

Guest Editors

Dr. Diane Baia-da-Silva

Instituto Leônidas & Maria Deane, ILMD/FIOCRUZ Amazonia, Manaus, Brazil

Dr. Gisely Cardoso De Melo

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil

Deadline for manuscript submissions

closed (29 February 2024)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/182652

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).